False-positive pregnancy tests in females of reproductive potential receiving lenalidomide in the United States

Figures & data

Table 1. Overview of enrolled and active patients in the REVLIMID REMS program during the 10-year period (27 December 2005 through 26 December 2015).

Characteristics	Total enrolled and active patients N = 193,828
Males, n (%)	108,275 (56.0)
Females, n (%)	85,553 (44.0)
All FRP, n	5768 (7.0% of females; 3.0% of all patients)
Age, median (range), years	47 (11–63)
Total drug dispenses, n	67,934
Drug dispense cycles per FRP, median (range)	6 (1–117)
FRP with false-positive pregnancy test results, n	130
No. of FRP with single false-positive pregnancy test results	48
No. of FRP with repeat false-positive pregnancy test results	82
Age, median (range), years	47 (26–58)
Total drug dispenses, n	2548
Drug dispense cycles per FRP, median (range)	15 (1–71)
Total false pregnancy test results, n  Median (range)	641 2 (1–47)

FRP: females of reproductive potential; REMS: risk evaluation and mitigation strategy.